Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on March 29, 2017. The report details the completion of a public offering of common stock, specifically the full exercise of an underwriter's option to purchase additional shares.
Key Financial Metrics
- Offering Completion: The underwriter, Ladenburg Thalmann & Co. Inc., exercised its option in full to purchase 561,497 additional shares.
- Share Price: Shares were sold to the public at $3.74 per share and purchased by the underwriter at $3.5156 per share.
- Net Proceeds (Option Exercise): Approximately $1.9 million from the sale of the additional shares.
- Total Net Proceeds (Full Offering): Approximately $14.6 million from the sale of 4,304,813 total shares.
- Expenses: Proceeds figures are net of underwriting discounts, commissions, and estimated offering expenses.
Material Changes
The primary material change is the increase in the company's cash liquidity resulting from the completion of the offering. The filing does not provide comparative financial data for prior periods as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The offering was conducted under a shelf registration statement on Form S-3 (No. 333-214859) declared effective on December 16, 2016. The filing includes a standard disclaimer that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful. No specific forward-looking guidance or risk factors beyond standard securities law disclaimers are detailed in this specific text.
Investor Verification Checklist
- Verify the total number of shares outstanding post-offering (4,304,813 shares sold in this offering).
- Confirm the use of proceeds as disclosed in the attached press release (Exhibit 99.1).
- Review the shelf registration statement (No. 333-214859) for broader offering terms.
- Check subsequent filings for updates on the company's cash position and burn rate.